Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
International Journal of Molecular Sciences · 26.12.2024 · 26 (1) · 88
DOI: 10.3390/ijms26010088 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.12.2024. Verfasst von Abdulaziz M Eshaq und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatstics, Milken Institute School of Public Health, George Washington University Washington, Washington, DC 20052,…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Skin Diseases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 330 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Immunotherapy, particularly that based on blocking checkpoint proteins in many tumors, including melanoma, Merkel cell carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast (TNB cancer), renal cancer, and gastrointestinal and endometrial neoplasms, is a therapeutic alternative to chemotherapy. Immune checkpoint inhibitor (ICI)-based therapies have the potential to target different pathways leading to the destruction of cancer cells. Although ICIs are an effective treatment strategy for patients with highly immune-infiltrated cancers, the development of different adverse effects including cutaneous adverse effects during and after the treatment with ICIs is common. ICI-associated cutaneous adverse effects include mostly inflammatory and bullous dermatoses, as well as severe cutaneous side reactions such as rash or inflammatory dermatitis encompassing erythema multiforme; lichenoid, eczematous, psoriasiform, and morbilliform lesions; and palmoplantar erythrodysesthesia. The development of immunotherapy-related adverse effects is a consequence of ICIs’ unique molecular action that is mainly mediated by the activation of cytotoxic CD4+/CD8+ T cells. ICI-associated cutaneous disorders are the most prevalent effects induced in response to anti-programmed cell death 1 (PD-1), anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and anti-programmed cell death ligand 1 (PD-L1) agents. Herein, we will elucidate the mechanisms regulating the occurrence of cutaneous adverse effects following treatment with ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatstics, Milken Institute School of Public Health, George Washington University Washington, Washington, DC 20052, USA.
- Research Laboratory of Surgery-Oncology, Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
- Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA 70112, USA.
- College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
- Department of Radiology, King Saud Medical City, Riyadh 11533, Saudi Arabia.
- Institut National de la Santé et de la Recherche Médicale, University of Strasbourg, 67000 Strasbourg, France.
ORCID-Profile: Mohamed Hassan
Zitieren
APA
Eshaq, A. M., Flanagan, T. W., Ba Abbad, A. A., Makarem, Z. A. A., Bokir, M. S., Alasheq, A. K., Al Asheikh, S. A., Almashhor, A. M., Binyamani, F., Al-Amoudi, W. A., Bawzir, A. S., Haikel, Y., Megahed, M., & Hassan, M. (2024). Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence. International Journal of Molecular Sciences, 26(1), 88. https://doi.org/10.3390/ijms26010088
Vancouver
Eshaq AM, Flanagan TW, Ba Abbad AA, Makarem ZAA, Bokir MS, Alasheq AK, et al. Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence. International Journal of Molecular Sciences. 2024;26(1):88. doi:10.3390/ijms26010088
BibTeX
@article{Eshaq2024,
author = {Eshaq, Abdulaziz M and Flanagan, Thomas W and Ba Abbad, Abdulqader A and Makarem, Zain Alabden A and Bokir, Mohammed S and Alasheq, Ahmed K and Al Asheikh, Sara A and Almashhor, Abdullah M and Binyamani, Faroq and Al-Amoudi, Waleed A and Bawzir, Abdulaziz S and Haikel, Youssef and Megahed, Mossad and Hassan, Mohamed},
title = {Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {26},
number = {1},
pages = {88},
doi = {10.3390/ijms26010088}
}
EUVIMED